CoChat

The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy

Open access
Wei, Yuan, Zhao, Qiyi, Gao, Zhiliang, Lao, Xiang-Ming, Lin, Wei-Ming, Chen, Dong-Ping, Mu, Ming, Huang, Chun-Xiang, Liu, Zheng-Yu, Li, Bo, Zheng, Limin, Kuang, Dong-Ming · 2019 · Journal of Clinical Investigation
Cited by 111

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

PD-L1 is a promising therapeutic target in aggressive cancers. However, immune landscapes and cancer hallmarks of human PD-L1+ tumors, as well as their roles in determining therapeutic efficacies are unknown. Here we identified, in detailed studies of gene data regarding 9769 patients of 32 types of human cancers, that PD-L1 could not exclusively represent IFN-γ signature and potentially signified pro-inflammatory myeloid responses in a tumor. PD-L1 heterogeneity endowed by local immune landscapes controlled cancer hallmarks and clinical outcomes of patients. Mechanically, NF-κB signal elicited by macrophage inflammatory responses generated PD-L1+ cancer cells exhibiting capabilities to aggressively survive, support angiogenesis, and metastasize, whereas STAT1 signal triggered by activated T cells induced PD-L1+ cancer cells susceptive to apoptosis. Importantly, PD-L1+ cancer cells generated by macrophages established great resistance to conventional chemotherapy, cytotoxicity of tumor-specific effector T cells, and therapy of immune checkpoint blockade. Therapeutic strategy combining immune checkpoint blockade with macrophage depletion or NF-κB inhibition in vivo effectively and successfully elicited caner regression. Our results provide insight into the functional features of PD-L1+ tumors and suggest that strategies to influence functional activities of inflammatory cells may benefit immune checkpoint blockade therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci127726

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 111

Metadata

Authors
Wei, Y., Zhao, Q., Gao, Z., Lao, X.-M., Lin, W.-M., Chen, D.-P., Mu, M., Huang, C.-X., Liu, Z.-Y., Li, B., Zheng, L., & Kuang, D.-M.
Venue
Journal of Clinical Investigation
Published
2019-07-15
Volume
129
Issue
8
Pages
3347-3360
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W2945755907
Cited by
111
References
14
FWCI
5.26
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy. https://app.cochat.ai/papers/10.1172/jci127726
The paper
Wei, Y., Zhao, Q., Gao, Z., Lao, X.-M., Lin, W.-M., Chen, D.-P., Mu, M., Huang, C.-X., Liu, Z.-Y., Li, B., Zheng, L., & Kuang, D.-M. (2019). The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy. Journal of Clinical Investigation. https://doi.org/10.1172/jci127726

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.